Evidence map›Paper›PMID 34696697›Full record

ReviewCancer biology & therapy2021

Multimodality therapy in metastatic pancreas cancer with a

Thomas L Sutton, Aaron Grossberg, Frederick Ey, Eileen M O'Reilly, Brett C Sheppard

Open access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Thomas L SuttonDepartment of Surgery, Oregon Heath & Science University (OHSU), Portland, Oregon, USA.ORCID 0000-0002-2894-7154
Aaron GrossbergDepartment of Radiation Medicine, OHSU, Portland, Oregon, USA.
Frederick EyDepartment of Hematology/Oncology, OHSU, Portland, Oregon, USA.
Eileen M O'ReillyDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Brett C SheppardDepartment of Surgery, Oregon Heath & Science University (OHSU), Portland, Oregon, USA.
Oregon Health & Science University · USUniversity of Portland · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Metastatic pancreatic adenocarcinoma (PDAC) is a rapidly lethal disease, with less than half of patients surviving 12 months, and 5-year survival approximately 3%. These outcomes are in large part due to a lack of effective medical and surgical therapies for metastatic PDAC. Herein, we present the case of a patient with oligometastatic liver recurrence of

Indexed as

AdenocarcinomaPancreatic NeoplasmsBiologyGerm-Line MutationHumansMutationNeoplasm Recurrence, LocalBRCA2cancer biologycomplete radiographic responselong-term survivalmetastasectomyolaparibPancreatic adenocarcinomaradiotherapy

Identifiers

PMID34696697
PMCPMC8726708
OpenAlexW3209779397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.